Press releases
Novasep announces 2016 financial results
Sales are up 3.5% at 271 M€
EBITDA is stable at 28 M€
Novasep appoints Xavier de Saint Guilhem as Chief Financial Officer
CFO appointment comes as the company gets ready for the next phase of its growth strategy
Novasep opens €11M new antibody-drug conjugate (ADC) bioconjugation unit
ADCs, used in innovative treatments against cancer, will be produced in Le Mans, France to serve international markets
Novasep Invests in a €27m Viral Vector Production Facility
The strategic investment supports the growing demand for development and commercial phase production of viral-vector based therapies
Three Novasep custom manufacturing sites renew FDA approval in 2016
Successful FDA inspections confirm Novasep’s longstanding reputation in maintaining
quality assurance systems fully compliant with the highest world standards
Novasep sells U.S. subsidiary TangenX Technology Corporation, innovator in tangential flow filtration for biopharmaceuticals
Transaction allows Novasep to accelerate strategic project plan
VRI, ANRS and Novasep sign an agreement for the cGMP manufacture of two experimental vaccines for the prevention and treatment of HIV-1/AIDS
Two candidate vaccines targeting dendritic cells have been developed at the Vaccine Research Institute (VRI), and their manufacture under cGMP guidelines will permit the set-up of future clinical trials in humans.
Novasep and Japanese agent AR Brown extend partnership
Stronger local representation in growing Japanese biopharma market will improve Novasep’s capacity to equip and service Japanese clients
Refinancing - Financial information about Exchange Notes and Warrants
Lyon, France, November 3, 2016
NOVASEP ANNOUNCES THE SUCCESS OF ITS REFINANCING
- Successful outcome of Exchange Offer and Consent Solicitation
- Participation of 96.26% of the principal amount of Existing Notes held by holders other than Novasep or its Affiliates